Endoparasitic infections in dogs from rural areas in the Lobos District, Buenos Aires province, Argentina

Dogs are definite hosts for several zoonotic helminthes and protozoan. Rural areas from the Lobos District in the northeast of Buenos Aires province, Argentina, are mainly used for livestock activity, increasing in this way the number of dogs on farms as well as the human risk of parasitic infections. The aims of this research were to evaluate the endoparasitic infections in dogs from farms in the Lobos District and analyze their zoonotic importance as well as several risk practices and habits of the rural population. Forty-two dog fecal samples obtained in 21 farms were analyzed through coproparasitological methods and coproantigen tests, which resulted in an overall parasite prevalence of 69.05% and 80.95% of the parasitized farms. The most frequent parasites were Trichuris vulpis and Eucoleus aerophila (26.19%), Echinococcus granulosus (19.05%), Uncinaria stenocephala and coccids (14.29%). The analysis of epidemiological files showed several habits of the rural population considered as risk factors associated with the presence of fecal samples parasitized and the presence of E. granulosus on the farms. It is clear that people involved with the farms studied were exposed to several helminthes that could cause serious diseases like cystic echinococcosis, which can become an important public health issue and affect the economy worldwideOs cães são hospedeiros definitivos de vários helmintos e protozoários zoonóticos. As áreas rurais do distrito de Lobos, no nordeste da província de Buenos Aires, Argentina, destinam-se principalmente à atividade pecuária aumentando desta forma o número de cães em fazendas, bem como o risco humano de infecções parasitárias. Os objetivos desta pesquisa foram avaliar as infecções endoparasitas em cães de fazendas do distrito de Lobos e analisar a sua importância zoonótica, bem como as práticas de risco e hábitos da população rural. Quarenta e duas amostras de fezes de cães obtidos em 21 fazendas foram analisadas pelos métodos coproparasitológicos e testes de coproantígenos, resultando numa prevalência de parasitas de 69,05% e 80,95% das propriedades parasitados. Os parasitas mais frequentes foram Trichuris vulpis e Eucoleus aerophila (26,19%), Echinococcus granulosus (19,05%), Uncinaria stenocephala e coccídeos (14,29%). A análise dos arquivos epidemiológicos mostraram vários hábitos da população rural como fatores de risco associados com a presença de amostras fecais parasitadas e a presença de E. granulosus em propriedades rurais. É evidente que as pessoas das fazendas estudadas foram expostas a vários helmintos que podem causar doenças graves como equinococose cística, que constitui importante problema de saúde pública e econômico a nível mundial.Fil: Dopchiz, Marcela Cecilia. Universidad Nacional de Mar del Plata. Facultad de Ciencias Exactas y Naturales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Lavallén, Carla Mariela. Universidad Nacional de Mar del Plata. Facultad de Ciencias Exactas y Naturales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Bongiovanni, Roberto Antonio. Municipalidad de Lobos. Departamento de Bromatología y Zoonosis. Lobos; ArgentinaFil: Gonzalez, Patricia Verónica. Universidad Nacional de Mar del Plata. Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Elissondo, María Celina. Universidad Nacional de Mar del Plata. Facultad de Ciencias Exactas y Naturales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Yannarella, Francisco. Universidad Nacional de La Plata; ArgentinaFil: Denegri, Guillermo Maria. Universidad Nacional de Mar del Plata. Facultad de Ciencias Exactas y Naturales; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin

Antifungal protection by endophytic bacteria in legumes

PosterPeanut and chickpea are two of the major crops cultivated in Argentina Two different fungal diseases generate substantial yield losses annually Ascochyta rabiei causal agent of aschochyta blight and Thecaphora frezii is the causal agent of peanut smut Beneficial bacteria have the potential to provide antifungal effects that could be used as bioproducts to control these diseases Our project aims to identify endophytic bacteria with antifungal effects in vitro and in vivo.Instituto de Fisiología y Recursos Genéticos VegetalesFil: Valetti, Lucio. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patología Vegetal; ArgentinaFil: Valetti, Lucio. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Fitopatología y Modelización Agrícola (UFyMA); ArgentinaFil: Sardo, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Fitopatología y Modelización Agrícola (UFyMA); ArgentinaFil: Sardo, María Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patología Vegetal; ArgentinaFil: Posada, Gisella. Instituto Superior Albert Sabin; ArgentinaFil: Gonzalez, Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Fisiología y Recursos Genéticos Vegetales; ArgentinaFil: Gonzalez, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Estudios Agropecuarios (UDEA) ; ArgentinaFil: Parola, Rodrigo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Fisiología y Recursos Genéticos Vegetales; ArgentinaFil: Parola, Rodrigo. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Estudios Agropecuarios (UDEA) ; ArgentinaFil: Paredes, Juan Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Fitopatología y Modelización Agrícola (UFyMA); ArgentinaFil: Paredes, Juan Andrés. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patología Vegetal; ArgentinaFil: Monguillot, Joaquín Humberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Fitopatología y Modelización Agrícola (UFyMA); ArgentinaFil: Monguillot, Joaquín Humberto. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patología Vegetal; ArgentinaFil: Ruiz, O.A. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto Tecnológico de Chascomús (INTECH); Argentna. Universidad Nacional de San Martín; ArgentinaFil: Guzzo, María Carla. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Fisiología y Recursos Genéticos Vegetales; ArgentinaFil: Guzzo, María Carla. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Estudios Agropecuarios (UDEA) ; ArgentinaFil: Monteoliva, Mariela Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Fisiología y Recursos Genéticos Vegetales; ArgentinaFil: Monteoliva, Mariela Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Estudios Agropecuarios (UDEA) ; Argentin

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30–79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30–79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306–359) million women and 317 (292–344) million men in 1990 to 626 (584–668) million women and 652 (604–698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55–62) of women and 49% (46–52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43–51) of women and 38% (35–41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20–27) for women and 18% (16–21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings

Selección de bacterias por su capacidad antagonista del crecimiento de Thecaphora frezzi para su uso como biocontrol del carbón del maní

PosterUna de las principales enfermedades que afectan la producción de maní en Argentina es el carbón de maní, ocasionado por el hongo Thecaphora frezii. El uso de microorganismos biocontroladores para el manejo de enfermedades vegetales es una estrategia sustentable y amigable con el ambiente ya que por antagonismo, inhibe el crecimiento del patógeno y reduce su efecto sobre el fruto.Instituto de Patología VegetalFil: Gonzalez, Pablo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Fisiología y Recursos Genéticos Vegetales; ArgentinaFil: Gonzalez, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Estudios Agropecuarios (UDEA) ; ArgentinaFil: Guzzo, María Carla. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Fisiología y Recursos Genéticos Vegetales; ArgentinaFil: Guzzo, María Carla. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Estudios Agropecuarios (UDEA) ; ArgentinaFil: Parola, Rodrigo. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Fisiología y Recursos Genéticos Vegetales; ArgentinaFil: Parola, Rodrigo. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Estudios Agropecuarios (UDEA) ; ArgentinaFil: Monteoliva, Mariela Ines. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Fisiología y Recursos Genéticos Vegetales; ArgentinaFil: Monteoliva, Mariela Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Estudios Agropecuarios (UDEA) ; ArgentinaFil: Valetti, Lucio. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Patología Vegetal; ArgentinaFil: Valetti, Lucio. Consejo Nacional de Investigaciones Científicas y Técnicas. Unidad de Fitopatología y Modelización Agrícola (UFyMA); Argentin

Small heat shock proteins and the postharvest chilling tolerance of tomato fruit

Plants have the largest number of small heat shock proteins (sHsps) (15–42 kDa) among eukaryotes, but little is known about their function in vivo. They accumulate in response to different stresses, and specific sHsps are also expressed during developmental processes such as seed development, germination, and ripening. The presence of organelle-specific sHsps appears to be unique to plants. The sHsps expression is regulated by heat stress transcription factors (Hsfs). In this work, it was explored the role of sHsps in the chilling injury of tomato fruit. The level of transcripts and proteins of cytoplasmic and organellar sHsps was monitored in fruit during ripening and after cold storage (4 weeks at 4°C). Expression of HsfA1, HsfA2, HsfA3, and HsfB1 was also examined. Two cultivars of tomato (Solanum lycopersicum) contrasting in chilling tolerance were assayed: Micro-Tom (chilling-tolerant) and Minitomato (chilling-sensitive). Results showed that sHsps were induced during ripening in fruit from both cultivars. However, sHsps were induced in Micro-Tom fruit but not in Minitomato fruit after storage at a low temperature. In particular, sHsp 17.4-CII and sHsp23.8-M transcripts strongly accumulated in Micro-Tom fruit and HsfA3 transcript diminished after cold storage. These data suggest that sHsps may be involved in the protection mechanisms against chilling stress and substantiate the hypothesis that sHsps may participate in the mechanism of tomato genotype chilling tolerance.Fil: Re, Martin Damian. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Gonzalez, Carla. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Escobar, Mariela Raquel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Sossi, Maria Laura. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Valle, Estela Marta. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Boggio, Silvana Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Biología Molecular y Celular de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Instituto de Biología Molecular y Celular de Rosario; Argentin

Endoparasitic infections in dogs from rural areas in the Lobos District, Buenos Aires province, Argentina Infecçóes endoparasitas em cães de áreas rurais do distrito de Lobos, província de Buenos Aires, Argentina

Dogs are definite hosts for several zoonotic helminthes and protozoan. Rural areas from the Lobos District in the northeast of Buenos Aires province, Argentina, are mainly used for livestock activity, increasing in this way the number of dogs on farms as well as the human risk of parasitic infections. The aims of this research were to evaluate the endoparasitic infections in dogs from farms in the Lobos District and analyze their zoonotic importance as well as several risk practices and habits of the rural population. Forty-two dog fecal samples obtained in 21 farms were analyzed through coproparasitological methods and coproantigen tests, which resulted in an overall parasite prevalence of 69.05% and 80.95% of the parasitized farms. The most frequent parasites were Trichuris vulpis and Eucoleus aerophila (26.19%), Echinococcus granulosus (19.05%), Uncinaria stenocephala and coccids (14.29%). The analysis of epidemiological files showed several habits of the rural population considered as risk factors associated with the presence of fecal samples parasitized and the presence of E. granulosus on the farms. It is clear that people involved with the farms studied were exposed to several helminthes that could cause serious diseases like cystic echinococcosis, which can become an important public health issue and affect the economy worldwide.<br>Os c&#227;es s&#227;o hospedeiros definitivos de v&#225;rios helmintos e protozo&#225;rios zoon&#243;ticos. As &#225;reas rurais do distrito de Lobos, no nordeste da prov&#237;ncia de Buenos Aires, Argentina, destinam-se principalmente &#224; atividade pecu&#225;ria aumentando desta forma o n&#250;mero de c&#227;es em fazendas, bem como o risco humano de infec&#231;&#245;es parasit&#225;rias. Os objetivos desta pesquisa foram avaliar as infec&#231;&#245;es endoparasitas em c&#227;es de fazendas do distrito de Lobos e analisar a sua import&#226;ncia zoon&#243;tica, bem como as pr&#225;ticas de risco e h&#225;bitos da popula&#231;&#227;o rural. Quarenta e duas amostras de fezes de c&#227;es obtidos em 21 fazendas foram analisadas pelos m&#233;todos coproparasitol&#243;gicos e testes de coproant&#237;genos, resultando numa preval&#234;ncia de parasitas de 69,05% e 80,95% das propriedades parasitados. Os parasitas mais frequentes foram Trichuris vulpis e Eucoleus aerophila (26,19%), Echinococcus granulosus (19,05%), Uncinaria stenocephala e cocc&#237;deos (14,29%). A an&#225;lise dos arquivos epidemiol&#243;gicos mostraram v&#225;rios h&#225;bitos da popula&#231;&#227;o rural como fatores de risco associados com a presen&#231;a de amostras fecais parasitadas e a presen&#231;a de E. granulosus em propriedades rurais. &#201; evidente que as pessoas das fazendas estudadas foram expostas a v&#225;rios helmintos que podem causar doen&#231;as graves como equinococose c&#237;stica, que constitui importante problema de sa&#250;de p&#250;blica e econ&#244;mico a n&#237;vel mundial